New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisal

Authors

  • Simona Lattanzi Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona - Italy https://orcid.org/0000-0001-8748-0083

DOI:

https://doi.org/10.33393/grhta.2022.2420

Keywords:

Antiseizure Medications, Epilepsy, Focal Seizures

Abstract

Anti-seizure medications (ASMs) represent the pillar of the treatment of epilepsy. The rate of drug-resistant epilepsy remained substantially unchanged over time and there is still the need for new and more effective treatment options. Brivaracetam, cenobamate, eslicarbazepine acetate, lacosamide and perampanel are ‘third-generation’ ASMs.

The aim of this article is to summarize the currently available evidence about the relative efficacy and tolerability of the ‘third-generation’ ASMs as adjunctive treatment of focal-onset seizures in adults.

So far, no randomized controlled study directly compared these ASMs, and their comparative efficacy and tolerability have been indirectly evaluated by one network meta-analysis. Sixteen trials were included in the network meta-analysis. The efficacy endpoints were the rates of seizure response and seizure freedom, defined as ≥ 50% and 100% reduction in baseline monthly seizure frequency. The tolerability endpoints were the rate of patients who developed any treatment emergent adverse events (TEAEs) and any TEAE leading to drug discontinuation. Cenobamate had the greatest likelihood of being the best option for the ≥ 50% and 100% seizure frequency reduction. Brivaracetam and lacosamide had the greatest likelihood to rank as the best-tolerated treatments for the occurrence of any TEAE and TEAE leading to discontinuation.

Although network meta-analyses are not substitutes of direct comparisons, they can provide valuable evidence about the hierarchy of interventions. Additional real-world data can be useful complement to characterize the clinical profile and therapeutic potentialities of third-generation ASMs.

References

  1. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy – a review. Epilepsy Res. 2009;85(1):31-45. https://doi.org/10.1016/j.eplepsyres.2009.03.003PMID:19369037 DOI: https://doi.org/10.1016/j.eplepsyres.2009.03.003
  2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the ‘common’ neurologic disorders? Neurology. 2007;68(5):326-337. https://doi.org/10.1212/01.wnl.0000252807.38124.a3 PMID:17261678 DOI: https://doi.org/10.1212/01.wnl.0000252807.38124.a3
  3. Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58(5):764-771. https://doi.org/10.1111/epi.13723 PMID:28345152 DOI: https://doi.org/10.1111/epi.13723
  4. Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59-70. https://doi.org/10.1016/j.yebeh.2014.05.031 PMID:24980390 DOI: https://doi.org/10.1016/j.yebeh.2014.05.031
  5. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346(8968):140-144. https://doi.org/10.1016/S0140-6736(95)91208-8 PMID:7603228 DOI: https://doi.org/10.1016/S0140-6736(95)91208-8
  6. Lattanzi S, Zaccara G, Giovannelli F, et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139(1):33-41. https://doi.org/10.1111/ane.13025 PMID:30194755 DOI: https://doi.org/10.1111/ane.13025
  7. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279-286. https://doi.org/10.1001/jamaneurol.2017.3949PMID:29279892 DOI: https://doi.org/10.1001/jamaneurol.2017.3949
  8. Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of ‘Third-Generation’ antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs. 2017;31(11):959-974. https://doi.org/10.1007/s40263-017-0480-6 PMID:29204953 DOI: https://doi.org/10.1007/s40263-017-0480-6
  9. Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82(2):199-218. https://doi.org/10.1007/s40265-021-01661-4PMID:35061214 DOI: https://doi.org/10.1007/s40265-021-01661-4
  10. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia. 2007;48(7):1303-1307. https://doi.org/10.1111/j.1528-1167.2007.01136.x PMID:17521343 DOI: https://doi.org/10.1111/j.1528-1167.2007.01136.x
  11. Brivaracetam. Summary of product characteristic. https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf (Accessed April 2022).
  12. Cenobamate. Summary of product characteristic. https://www.ema.europa.eu/en/documents/product-information/ontozry-epar-product-information_en.pdf (Accessed April 2022).
  13. Eslicarbazepine acetate. Summary of product characteristic. https://www.ema.europa.eu/en/documents/product-information/zebinix-epar-product-information_en.pdf (Accessed April 2022).
  14. Lacosamide. Summary of product characteristic. https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_en.pdf (Accessed April 2022).
  15. Perampanel. Summary of product characteristic. https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf (Accessed April 2022).
  16. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80-97. https://doi.org/10.1002/jrsm.1037 PMID:26062083 DOI: https://doi.org/10.1002/jrsm.1037
  17. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57-66. https://doi.org/10.1111/epi.12433PMID:24446953 DOI: https://doi.org/10.1111/epi.12433
  18. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47-56. https://doi.org/10.1111/epi.12432 PMID:24256083 DOI: https://doi.org/10.1111/epi.12432
  19. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890-1898. https://doi.org/10.1111/epi.13212 PMID:26471380 DOI: https://doi.org/10.1111/epi.13212
  20. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38-48. https://doi.org/10.1016/S1474-4422(19)30399-0 PMID:31734103 DOI: https://doi.org/10.1016/S1474-4422(19)30399-0
  21. Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P; BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50(3):454-463. https://doi.org/10.1111/j.1528-1167.2008.01946.xPMID:19243424 DOI: https://doi.org/10.1111/j.1528-1167.2008.01946.x
  22. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P; BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120(5):281-287. https://doi.org/10.1111/j.1600-0404.2009.01218.x PMID:19832771 DOI: https://doi.org/10.1111/j.1600-0404.2009.01218.x
  23. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2-3):278-285. https://doi.org/10.1016/j.eplepsyres.2010.01.014 PMID:20299189 DOI: https://doi.org/10.1016/j.eplepsyres.2010.01.014
  24. Sperling MR, Abou-Khalil B, Harvey J, et al; 304 Study Team. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244-253. https://doi.org/10.1111/epi.12894 PMID:25528898 DOI: https://doi.org/10.1111/epi.12894
  25. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308-1317. https://doi.org/10.1111/j.1528-1167.2007.01188.x PMID:17635557 DOI: https://doi.org/10.1111/j.1528-1167.2007.01188.x
  26. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443-453. https://doi.org/10.1111/j.1528-1167.2008.01951.xPMID:19183227 DOI: https://doi.org/10.1111/j.1528-1167.2008.01951.x
  27. Chung S, Sperling MR, Biton V, et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958-967. https://doi.org/10.1111/j.1528-1167.2009.02496.x PMID:20132285 DOI: https://doi.org/10.1111/j.1528-1167.2009.02496.x
  28. Hong Z, Inoue Y, Liao W, et al; EP0008 Study Group. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study. Epilepsy Res. 2016;127:267-275. https://doi.org/10.1016/j.eplepsyres.2016.08.032 PMID:27669155 DOI: https://doi.org/10.1016/j.eplepsyres.2016.08.032
  29. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589-596. https://doi.org/10.1212/WNL.0b013e3182635735 PMID:22843280 DOI: https://doi.org/10.1212/WNL.0b013e3182635735
  30. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117-125. https://doi.org/10.1111/j.1528-1167.2012.03638.x PMID:22905857 DOI: https://doi.org/10.1111/j.1528-1167.2012.03638.x
  31. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408-1415. https://doi.org/10.1212/WNL.0b013e318254473a PMID:22517103 DOI: https://doi.org/10.1212/WNL.0b013e318254473a
  32. Nishida T, Lee SK, Inoue Y, Saeki K, Ishikawa K, Kaneko S. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018;137(4):392-399. https://doi.org/10.1111/ane.12883 PMID:29250772 DOI: https://doi.org/10.1111/ane.12883
  33. Cenobamate FDA. Full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf (Accessed April 2022).
  34. Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175-182. https://doi.org/10.1016/j.ejphar.2019.05.007 PMID:31063770 DOI: https://doi.org/10.1016/j.ejphar.2019.05.007
  35. Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117. https://doi.org/10.1016/j.ejphar.2020.173117 PMID:32325146 DOI: https://doi.org/10.1016/j.ejphar.2020.173117
  36. Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61(11):2329-2339. https://doi.org/10.1111/epi.16718 PMID:33063849 DOI: https://doi.org/10.1111/epi.16718
  37. Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609-618. https://doi.org/10.1007/s40263-021-00819-8 PMID:33993416 DOI: https://doi.org/10.1007/s40263-021-00819-8
  38. Rosenfeld WE, Abou-Khalil B, Aboumatar S, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016-3028. https://doi.org/10.1111/epi.17092 PMID:34633074 DOI: https://doi.org/10.1111/epi.17092
  39. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-1251. https://doi.org/10.1111/epi.13060 PMID:26114620 DOI: https://doi.org/10.1111/epi.13060
  40. Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090-1098. https://doi.org/10.1111/epi.16546PMID:32452532 DOI: https://doi.org/10.1111/epi.16546
  41. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472-475. https://doi.org/10.1136/bmj.326.7387.472 PMID:12609941 DOI: https://doi.org/10.1136/bmj.326.7387.472
  42. Thieffry S, Klein P, Baulac M, et al. Understanding the challenge of comparative effectiveness research in focal epilepsy: a review of network meta-analyses and real-world evidence on antiepileptic drugs. Epilepsia. 2020;61(4):595-609. https://doi.org/10.1111/epi.16476PMID:32201951 DOI: https://doi.org/10.1111/epi.16476
  43. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417-428. https://doi.org/10.1016/j.jval.2011.04.002 PMID:21669366 DOI: https://doi.org/10.1016/j.jval.2011.04.002
  44. Lattanzi S, Trinka E, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis. Epilepsia. 2019;60(11):2245-2254. https://doi.org/10.1111/epi.16366 PMID:31608438 DOI: https://doi.org/10.1111/epi.16366